We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
- Authors
Ferrarini, Isacco; Gandini, Francesca; Zapparoli, Ettore; Rigo, Antonella
- Abstract
Patients with chronic lymphocytic leukemia (CLL) relapsing on ibrutinib are often treated with the Bcl-2 inhibitor venetoclax. However, the transition from one agent to another poses some clinical challenges due to disease flares sometimes occurring right after ibrutinib interruption. Here, we describe three clinical vignettes highlighting two distinct patterns of ibrutinib-to-venetoclax transition. While patients following the favorable pattern transited to venetoclax without experiencing disease flare, the one patient who took the unfavorable path showed rapid disease rebound, with large-cell transformation occurring one week after ibrutinib interruption. A high burden of BTK and PLCG2 mutations was found only in patients with the favorable transition pattern, suggesting that removing BTK inhibition might be particularly harmful if CLL cells are progressing through mechanisms external to the BTK axis.
- Subjects
IBRUTINIB; VENETOCLAX; CHRONIC lymphocytic leukemia; PROGRESSION-free survival; CONFIDENCE intervals
- Publication
Current Oncology, 2022, Vol 29, Issue 4, p2792
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29040227